Some clinical trials are assessing the efficiency of the combination anti-PD-1/PD-L1 and anti-CTLA-4 for instance, A phase I/II study evaluating the efficacy and safety of AK104, a bispecific antibody against CTLA-4 and PD-1 in relapse/refractory T cell lymphoma, melanoma, and advanced solid tumors (NCT04444141; NCT04172454). The gene discussed is PDCD1; the disease is melanoma.